Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of sales | 34 | 23 | 64 | 52 |
| Research and development | 167 | 165 | 354 | 331 |
| Selling, general and administrative | 88 | 87 | 176 | 174 |
| Total operating expenses | 289 | 275 | 594 | 557 |
| Loss from operations | (75) | (108) | (244) | (251) |
| Interest income | 5 | 6 | 11 | 13 |
| Non-cash interest expense on liabilities for sales of future royalties | (22) | (14) | (43) | (28) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's SG&A?
- Ultragenyx Pharmaceutical (RARE) reported SG&A of $88M in Q2 2026.
- How has Ultragenyx Pharmaceutical's SG&A changed year-over-year?
- Ultragenyx Pharmaceutical's SG&A increased by 1.1% year-over-year, from $87M to $88M.
- What is the long-term trend for Ultragenyx Pharmaceutical's SG&A?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's SG&A has grown at a 12.2% compound annual growth rate (CAGR), from $219.98M to $348.56M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Ultragenyx Pharmaceutical's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude